TY - JOUR
T1 - miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers
AU - Du, Liqin
AU - Subauste, Maria C.
AU - DeSevo, Christopher
AU - Zhao, Zhenze
AU - Baker, Michael
AU - Borkowski, Robert
AU - Schageman, Jeoffrey J.
AU - Greer, Rachel
AU - Yang, Chin Rang
AU - Suraokar, Milind
AU - Wistuba, Ignacio I.
AU - Gazdar, Adi F.
AU - Minna, John D.
AU - Pertsemlidis, Alexander
N1 - Funding Information:
High performance computing hardware was provided by an Academic Excellence Grant from Sun Microsystems. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
PY - 2012/6/18
Y1 - 2012/6/18
N2 - NSCLC (non-small cell lung cancer) often exhibits resistance to paclitaxel treatment. Identifying the elements regulating paclitaxel response will advance efforts to overcome such resistance in NSCLC therapy. Using in vitro approaches, we demonstrated that over-expression of the microRNA miR-337-3p sensitizes NCI-H1155 cells to paclitaxel, and that miR-337-3p mimic has a general effect on paclitaxel response in NSCLC cell lines, which may provide a novel adjuvant strategy to paclitaxel in the treatment of lung cancer. By combining in vitro and in silico approaches, we identified STAT3 and RAP1A as direct targets that mediate the effect of miR-337-3p on paclitaxel sensitivity. Further investigation showed that miR-337-3p mimic also sensitizes cells to docetaxel, another member of the taxane family, and that STAT3 levels are significantly correlated with taxane resistance in lung cancer cell lines, suggesting that endogenous STAT3 expression is a determinant of intrinsic taxane resistance in lung cancer. The identification of a miR-337-3p as a modulator of cellular response to taxanes, and STAT3 and RAP1A as regulatory targets which mediate that response, defines a novel regulatory pathway modulating paclitaxel sensitivity in lung cancer cells, which may provide novel adjuvant strategies along with paclitaxel in the treatment of lung cancer and may also provide biomarkers for predicting paclitaxel response in NSCLC.
AB - NSCLC (non-small cell lung cancer) often exhibits resistance to paclitaxel treatment. Identifying the elements regulating paclitaxel response will advance efforts to overcome such resistance in NSCLC therapy. Using in vitro approaches, we demonstrated that over-expression of the microRNA miR-337-3p sensitizes NCI-H1155 cells to paclitaxel, and that miR-337-3p mimic has a general effect on paclitaxel response in NSCLC cell lines, which may provide a novel adjuvant strategy to paclitaxel in the treatment of lung cancer. By combining in vitro and in silico approaches, we identified STAT3 and RAP1A as direct targets that mediate the effect of miR-337-3p on paclitaxel sensitivity. Further investigation showed that miR-337-3p mimic also sensitizes cells to docetaxel, another member of the taxane family, and that STAT3 levels are significantly correlated with taxane resistance in lung cancer cell lines, suggesting that endogenous STAT3 expression is a determinant of intrinsic taxane resistance in lung cancer. The identification of a miR-337-3p as a modulator of cellular response to taxanes, and STAT3 and RAP1A as regulatory targets which mediate that response, defines a novel regulatory pathway modulating paclitaxel sensitivity in lung cancer cells, which may provide novel adjuvant strategies along with paclitaxel in the treatment of lung cancer and may also provide biomarkers for predicting paclitaxel response in NSCLC.
UR - http://www.scopus.com/inward/record.url?scp=84862501903&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862501903&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0039167
DO - 10.1371/journal.pone.0039167
M3 - Article
C2 - 22723956
AN - SCOPUS:84862501903
SN - 1932-6203
VL - 7
JO - PloS one
JF - PloS one
IS - 6
M1 - e39167
ER -